All In Biotech

Drug Trial Radar · NCT07768358

Tucatinib Continuation Study

TUCATINIB CONTINUATION PROTOCOL: AN OPEN-LABEL STUDY FOR PARTICIPANTS FROM TUCATINIB CLINICAL STUDIES

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

175

Planned (sponsor's estimate)

Start

Nov 6, 2026

Primary completion

Mar 13, 2032

Study completion Mar 13, 2032

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment. These participants were part of Pfizer-sponsored tucatinib parent studies that will be closed. Additional follow-up safety information will be collected. This will allow further understanding of the safety profile of tucatinib in participants who continue to receive the study treatment.

Conditions

  • HER2-positive Breast Cancer
  • Cervical Cancer
  • Biliary Tract Neoplasms
  • Urothelial Cancer
  • Advanced Non-Small Cell Lung Cancer
  • Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
  • Colorectal Cancer

Interventions

  • tucatinibDrug

    150 - 300 mg, by mouth, twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To monitor the safety and tolerability of tucatinibTime frame: Up to approximately 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.